Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients

References

• De Santis C, Naishadham D, Jemal A, et al. Cancer statistics for African Americans, 2013. CA Cancer J Clin. 2013;63(3):151–166.
   PubMed Web of Science ®Google Scholar
• Reck M, Popat S, Reinmuth N, et al. Metastatic non-small cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl. 3):27–39.
   Google Scholar
• Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150(6):1121–1134.
   PubMed Web of Science ®Google Scholar
• Lynch T, Bell D, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139.
   PubMed Web of Science ®Google Scholar
• Paez J, Janne P, Lee J, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci. 2004;101(36):13306–13311.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi Y, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature. 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Cohen B, Kiener P, Green J, et al. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem. 1996;271(48):30897–30903.
   PubMed Web of Science ®Google Scholar
• Grandis J, Sok J. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004;102(1):37–46.
   PubMed Web of Science ®Google Scholar
• Salomon D, Brandt R, Ciardiello F, et al. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183–232.
   PubMed Web of Science ®Google Scholar
• Fumarola C, Bonelli MA, Petronini PG, et al. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014;90(3):197–207.
   PubMed Web of Science ®Google Scholar
• Hirsch F, Varella-Garcia M, Bunn P, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer. J Clin Oncol. 2006;24(31):5034–5042.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch F, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643–655.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Dobashi Y, Sakurai H, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in non small cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005;103(6):1265–1273.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Cardona AF, Federico Bramuglia G, et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol. 2011;6(11):1955–1959.
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–967.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.
   PubMed Web of Science ®Google Scholar
• Tan CS, Cho BC, Soo RA. Treatment options for EGFR mutant NSCLC with CNS involvement- Can patients BLOOM with the use of next generation EGFR TKIs? Lung Cancer. 2017;108(6):29–37.
   PubMedGoogle Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomised, Phase III study. Lancet Oncol. 2011;12(8):735–742.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomised Phase III trial. Lancet Oncol. 2013;13(3):239–246.
   Web of Science ®Google Scholar
• Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never- smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–1128.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase III trial. Lancet Oncol. 2010;11(2):121–128.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–2874.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Zhou Q, Yan HH, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017;116(5):568–574.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sheng J, Kang S, et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One. 2014;9(9):e107161.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase III trial. Lancet Oncol. 2014;15(2):213–222.
   PubMed Web of Science ®Google Scholar
• Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–151.
   PubMed Web of Science ®Google Scholar
• Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a Phase IIB, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–589.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Tan EH, O’byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the Phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28(2):270–277.
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, Phase III trial. Lancet Oncol. 2017;18(11):1454–1466.
   PubMed Web of Science ®Google Scholar
• Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and egfr-activating mutations. J Clin Oncol. 2018;36(22):2244–2250.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv192–iv237.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(9):841–849.
   PubMed Web of Science ®Google Scholar
• Schicher N, Paulitschke V, Swoboda A, et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res. 2009;15(10):3495–3502.
   PubMed Web of Science ®Google Scholar
• Goldman CK, Kim J, Wong WL, et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993;4(1):121–133.
   PubMed Web of Science ®Google Scholar
• Hung MS, Chen IC, Lung JH, et al. Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer. Oncol Lett. 2016;12(6):4597–4604.
   Web of Science ®Google Scholar
• Li H, Takayama K, Wang S, et al. Addiction of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression. Cancer Chemother Pharmacol. 2014;74(6):1297–1305.
   PubMed Web of Science ®Google Scholar
• Herbst R, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377(9780):1846–1854.
   PubMed Web of Science ®Google Scholar
• Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–1244.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer (NSCLC): survival follow-up results of JO25567. J Clin Oncol. 2018;36(15 suppl):9007.
   Google Scholar
• Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–635.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Janne PA, Wang X, et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer. Jama Oncol. 2019;5(10):1448–1455.
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Garon EB, Seto T, et al. RELAY: a multinational, double blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). Presented at: 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; 2019 May 31–June 4; Chicago, IL.
   Google Scholar
• Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6(12):4885–4892.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drug activity in human cancer cells by ZD-1839(Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6(5):2053–2063.
   PubMed Web of Science ®Google Scholar
• Higgins B, Kolinsky K, Smith M, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs. 2004;15(5):503–512.
   PubMed Web of Science ®Google Scholar
• Okabe T, Okamoto I, Tsukioka S, et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther. 2008;7(3):599–606.
   PubMed Web of Science ®Google Scholar
• Li T, Ling YH, Goldman ID, et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 2007;13(11):3413–3422.
   PubMed Web of Science ®Google Scholar
• La Monica S, Madeddu D, Tiseo M, et al. Combination of gefitinib and pemetrexed prevents the acquisition of TKI resistance in NSCLC cell lines carrying EGFR-activating mutation. J Thorac Oncol. 2016;11(7):1051–1063.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Lemos C, Tekle C, et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol. 2008;73(4):1290–1300.
   PubMed Web of Science ®Google Scholar
• La Monica S, Minari R, Cretella D, et al. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. J Exp Clin Cancer Res. 2019;38(1):222.
   PubMedGoogle Scholar
• Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004;22(5):777–784.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004;22(5):785–793.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel in advanced non-small cell lung cancer. J Clin Oncol. 2005;23(25):5892–5899.
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol. 2007;25(12):1545–1552.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Murakami H, Yang PC, et al. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016;34(27):3258–3266.
   PubMed Web of Science ®Google Scholar
• Sugawara S, Oizumi S, Minato K, et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Ann Oncol. 2015;26(5):888–894.
   PubMed Web of Science ®Google Scholar
• Nakamura AIA, Morita S, Hosomi Y, et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). Presented at: ASCO meeting 2018; 2018 June 1–5; Chicago, IL.
   Google Scholar
• Noronha V, Josh A, Maruti Patil V et al. Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non small cell lung cancer. Presented at: ASCO meeting 2019; 2019 May 31–June 4; Chicago,IL.
   Google Scholar
• Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–838.
   PubMed Web of Science ®Google Scholar
• Wu JY, Yu CJ, Chang YC, et al. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812–3821.
   PubMed Web of Science ®Google Scholar
• Tu HY, Ke EE, Yang JJ, et al. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 2017;114:96–102.
   PubMed Web of Science ®Google Scholar
• Chiu CH, Yang CT, Shih JY, et al. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thoracic Oncol. 2015;10(5):793–799.
   PubMed Web of Science ®Google Scholar
• Passaro A, Prelaj A, Bonanno L, et al. Activity of EGFR TKIs in caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations. Clin Lung Cancer. 2019;20(2):e186–e194.
   PubMed Web of Science ®Google Scholar
• Klughammer B, Brugger W, Cappuzzo F, et al. Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations. J Thorac Oncol. 2016;11(4):545–555.
   PubMed Web of Science ®Google Scholar
• Leventakos K, Kipp BR, Rumilla KM, et al. Brief Report: S768I mutation in EGFR in patients with lung cancer. J Thorac Oncol. 2016;11(10):1798–1801.
   PubMed Web of Science ®Google Scholar
• Pallan L, Taniere P, Koh P, et al. Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases. J Thoracic Oncol. 2014;9(10):e75.
   PubMed Web of Science ®Google Scholar
• Kancha RK, von Bubnoff N, Peschel C, et al. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res. 2009;15(2):460–467.
   PubMed Web of Science ®Google Scholar
• Raghav D, Sharma V, Agarwal SM, et al. Structural investigation of deleterious non-synonymous SNPs of EGFR gene. Interdiscip Sci. 2013;5(1):60–68.
   PubMed Web of Science ®Google Scholar
• Shen YC, Tseng GC, Tu CY 1, et al. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung Cancer. 2017;110:56–62.
   PubMed Web of Science ®Google Scholar
• Brindel A, Althakfi W, Barritault M et al. Uncommon EGFR mutations in lung adenocarcinomas: clinical response to tyrosine kinase inhibitors. Presented at: ESMO 2018; 2018 October 19–23; Munich, Germany.
   Google Scholar
• Murray S, Dahabreh IJ, Linardou H, et al. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol. 2008;3(8):832–839.
   PubMed Web of Science ®Google Scholar
• Leduc C, Merlio JP, Besse B, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol. 2017;28(11):2715–2724.
   PubMed Web of Science ®Google Scholar
• Chung KP, Wu SG, Wu JY, et al. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Clin Cancer Res. 2012;18(12):3470–3477.
   PubMed Web of Science ®Google Scholar
• Improta G, Zupa A, Natalicchio MI, et al. Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. Med Oncol. 2018;35(3):28.
   PubMed Web of Science ®Google Scholar
• Rossi S, Toschi L, Finocchiaro G, et al. Impact of exon 19 deletion subtypes in EGFR-mutant metastatic non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors. Clin Lung Cancer. 2019;20(2):82–87.
   PubMed Web of Science ®Google Scholar
• Truini A, Starrett JH, Stewart T, et al. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research. 2019;25(21):6382–6391.
   PubMed Web of Science ®Google Scholar
• Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(1):24–31.
   Web of Science ®Google Scholar
• Keam B, Kim DW, Park J, et al. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol. 2014;19(4):594–600.
   PubMed Web of Science ®Google Scholar
• Rosell R, Dafni U, Felip E, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017;5(5):435–444.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Sima CS, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Lung Cancer. 2015;121(18):3212–3220.
   Google Scholar
• Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thoracic Oncol. 2013;8(2):179–184.
   PubMed Web of Science ®Google Scholar
• Hirano T, Yasuda H, Tani T, et al. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small cell lung cancer. Oncotarget. 2015;6(36):387–389.
   Google Scholar
• Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer. Nat Med. 2018;24(5):638–646.
   PubMed Web of Science ®Google Scholar
• Heymach J, Negrao M, Robichaux JP, et al. OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). J Thoracic Oncol. 2018;13(10):S323–S324.
   PubMed Web of Science ®Google Scholar
• Neal J, Doebele R, Riely G, et al. P1.13-44 safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC. J Thoracic Oncol. 2018;13(10):S599.
   Web of Science ®Google Scholar
• Janne PA, Neal JW, Camidge R et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Presented at: ASCO meeting 2019; 2019 May 31–June 4; Chicago,IL.
   Google Scholar
• Butler LM, Ferraldeschi R, Armstrong HK, et al. Maximizing the therapeutic potential of HSP90 inhibitors. Mol Cancer Res. 2015;13(11):1445–1451.
   PubMed Web of Science ®Google Scholar
• Felip E, Barlesi F, Besse B, et al. Brief report: phase 2 study of the HSP-90 inhibitor AUY922 in previously treated and molecularly defined patients with advanced non-small cell lung cancer. J Thoracic Oncol. 2017;13(4):576–584.
   PubMed Web of Science ®Google Scholar
• Jorge SE, Lucena-Araujo AR, Yasuda H, et al. EGFR Exon 20 insertion mutations display sensitivity to hsp90 inhibition in preclinical models and lung adenocarcinomas. Clin Cancer Res. 2018;24(24):6548–6555.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Costa GB, Oxnard GR, et al. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018;29(10):2092–2097.
   PubMed Web of Science ®Google Scholar